BII Biocompatibles

 
TIDMBII 
 
18 January 2011 
 
                       BIOCOMPATIBLES INTERNATIONAL PLC 
 
                      ("Biocompatibles" or the "Company") 
 
                              Additional Listing 
 
Farnham UK, 18 January 2011: Biocompatibles International plc (LSE:BII) 
announces that application has been made to the UK Listing Authority and the 
London Stock Exchange for a block listing of 1,000,000 ordinary shares of 21 53 
/94 pence each. The application is made in respect of shares to be issued 
pursuant to the exercise of awards under the Biocompatibles International plc 
Performance Share Plan. Admission of the new shares will become effective at 
8.00 a.m. on 19 January 2011. The new shares will, when issued rank pari passu 
with the existing ordinary share capital of the Company. 
 
                                    -Ends- 
 
Contact: 
 
Biocompatibles +44 (0)1252 732745 
 
Ian Ardill, Finance Director 
 
Lygia Jones, Assistant Company Secretary 
 
Dealing Disclosure Requirements 
 
Following the announcement made on Monday, 20 September 2010 that the Company 
is in an offer period for the purposes of the Takeover Code, the Company is 
required to restate the following: 
 
Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of 
any class of relevant securities of an offeree company or of any paper offeror 
(being any offeror other than an offeror in respect of which it has been 
announced that its offer is, or is likely to be, solely in cash) must make an 
Opening Position Disclosure following the commencement of the offer period and, 
if later, following the announcement in which any paper offeror is first 
identified. An Opening Position Disclosure must contain details of the person's 
interests and short positions in, and rights to subscribe for, any relevant 
securities of each of (i) the offeree company and (ii) any paper offeror(s). An 
Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be 
made by no later than 3.30 pm (London time) on the 10th business day following 
the commencement of the offer period and, if appropriate, by no later than 3.30 
pm (London time) on the 10th business day following the announcement in which 
any paper offeror is first identified. Relevant persons who deal in the 
relevant securities of the offeree company or of a paper offeror prior to the 
deadline for making an Opening Position Disclosure must instead make a Dealing 
Disclosure. 
 
Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% 
or more of any class of relevant securities of the offeree company or of any 
paper offeror must make a Dealing Disclosure if the person deals in any 
relevant securities of the offeree company or of any paper offeror. A Dealing 
Disclosure must contain details of the dealing concerned and of the person's 
interests and short positions in, and rights to subscribe for, any relevant 
securities of each of (i) the offeree company and (ii) any paper offeror, save 
to the extent that these details have previously been disclosed under Rule 8. A 
Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no 
later than 3.30 pm (London time) on the business day following the date of the 
relevant dealing. If two or more persons act together pursuant to an agreement 
or understanding, whether formal or informal, to acquire or control an interest 
in relevant securities of an offeree company or a paper offeror, they will be 
deemed to be a single person for the purpose of Rule 8.3. 
 
Opening Position Disclosures must also be made by the offeree company and by 
any offeror and Dealing Disclosures must also be made by the offeree company, 
by any offeror and by any persons acting in concert with any of them (see Rules 
8.1, 8.2 and 8.4). 
 
Details of the offeree and offeror companies in respect of whose relevant 
securities Opening Position Disclosures and Dealing Disclosures must be made 
can be found in the Disclosure Table on the Takeover Panel's website at 
www.thetakeoverpanel.org.uk, including details of the number of relevant 
securities in issue, when the offer period commenced and when any offeror was 
first identified. If you are in any doubt as to whether you are required to 
make an Opening Position Disclosure or a Dealing Disclosure, you should contact 
the Panel's Market Surveillance Unit on +44 (0)20 7638 0129. 
 
Biocompatibles International plc (www.biocompatibles.com) 
 
Biocompatibles International plc is a leading medical technology company in the 
field of drug-device combination products. 
 
The Oncology Products Division supplies medical devices from facilities in 
Farnham, UK and Oxford, CT. These include Drug-Eluting Bead Products which are 
used in more than 40 countries for the treatment of primary liver cancer (HCC), 
liver metastases from colorectal cancer, and other cancers; and Brachytherapy 
products (Radiation-Delivering Seeds) which are used in the treatment of 
prostate cancer. Our distribution partners include AngioDynamics Inc., Terumo 
Corporation and Eisai Co. Ltd. We have a clinical collaboration agreement with 
Bayer Healthcare Pharmaceuticals Inc. 
 
Our Licensing Division includes CellMed, in Alzenau, Germany, which is 
developing a Drug-Eluting Bead product for the treatment of stroke, based on 
proprietary stem cell technology; a GLP-1 analogue for the treatment of 
diabetes and obesity partnered with AstraZeneca; and a cosmetic Dermatology 
Bead partnered with Merz Pharmaceuticals GmbH. We also have a PC Licensing 
agreement with Medtronic Inc. in the field of Drug-Eluting Stents. 
 
 
 
END 
 

Biocompatibles (LSE:BII)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Biocompatibles (LSE:BII)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024